SYDNEY, Oct. 19, 2015 /PRNewswire/ -- Benitec Biopharma
Limited (NASDAQ: BNTC; ASX: BLT), a clinical-stage biotechnology
company developing innovative therapeutics based on its patented
gene-silencing technology called ddRNAi or 'expressed RNAi', today
announced the formation of its Hepatology Clinical Advisory
Board. The newly appointed Clinical Advisory Board will serve
as a strategic resource to Benitec as it continues to develop
therapies for the treatment of hepatitis B and C.
Benitec CEO and Managing Director Dr French said, "We are proud
to have assembled such a Board of world experts in hepatology. The
insight and guidance provided by our Clinical Advisors is a major
asset in promoting the successful development of our RNAi-based
therapeutics for the treatment of hepatitis B and C."
The inaugural members of the Hepatology Advisory Board
include:
Geoffrey McCaughan, PhD, MD,
MBBS, FRACP, AW Morrow Professor of Medicine at the Royal
Prince Alfred Hospital and the University of
Sydney, and Head of the Liver Injury & Cancer
Program at the Centenary Institute, Sydney, Australia
Harry Janssen, PhD, MD,
Professor of Medicine, Francis Family Chair in Liver Research and
Head of Liver Clinic at Toronto Western and Toronto General
Hospital, University Health Network, Toronto, Canada
Keyur Patel, MD, Associate
Professor of Medicine, Toronto Western Liver Clinic, University
Health Network, Toronto,
Canada
About Benitec Biopharma Limited:
Benitec Biopharma
Limited (NASDAQ: BNTC; ASX: BLT) is a clinical-stage biotechnology
company developing innovative therapeutics based on its patented
gene-silencing technology called ddRNAi or 'expressed RNAi'. Based
in Sydney, Australia with labs in
Hayward, CA (USA) and
collaborators and licensees around the world, the company is
developing ddRNAi-based therapeutics for chronic and
life-threatening human conditions including hepatitis C and B, wet
age-related macular degeneration and OPMD. Benitec has also
licensed ddRNAi to other biopharmaceutical companies for
applications including HIV/AIDS, Huntington's disease, chronic
neuropathic pain and retinitis pigmentosa. For further information
regarding Benitec and its activities, please contact the persons
below, or visit the Benitec website at www.benitec.com.
Contacts:
|
|
|
Company
|
Investor
relations
|
United
States
|
Carl
Stubbings
Chief Business
Officer
Tel: +61 (2) 9555
6986
Email:
cstubbings@benitec.com
|
Kyahn
Williamson
Buchan
Consulting
Tel: +61 (3) 9866
4722
Email:
kwilliamson@buchanwe.com.au
|
Tiberend Strategic
Advisors, Inc.
Joshua Drumm, Ph.D.
(Investors)
Tel: +1 212 375
2664
Email:
jdrumm@tiberend.com
Andrew Mielach
(Media)
Tel: +1 212 375
2694
Email:
amielach@tiberend.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/benitec-forms-hepatology-clinical-advisory-board-300161711.html
SOURCE Benitec Biopharma